Congratulations to Dr. Michael Walsh and Dr. Amit Garg and teams for being selected for funding by the Canadian Institutes for Health Research (CIHR)’s Accelerating Clinical Trials (ACT) Consortium! Of the 43 trials that applied for funding, 2 of the 11 trials selected were CNTN endorsed trials: 


Dr. Amit Garg (London, ON; Western University and the London Health Sciences Centre): Effect of a Multi-Component Quality Improvement Intervention on Patient Access to Kidney Transplantation and Living Kidney Donation (EnAKT-LKD)

Dr. Michael Walsh (Hamilton, ON; McMaster University and the Population Health Research Institute): Aldosterone blockade for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) 


The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit

This most recent call for proposals was designed to support ongoing and active, Canadian-led, high-impact RCTs that required additional funding for successful completion. All recipients of this ACT grant will publicly report their results by January 15, 2025. 


We look forward to learning their results!